{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 39,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 20,
  "notes": "The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/11",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.045,
        "w": 0.855,
        "x": 0.076,
        "y": 0.868
      },
      "kind": "disclaimer",
      "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-520. Clinical investigation of NVL-520 is ongoing.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e06bc86-b1e9-407b-b203-67057b8cd0e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.575,
        "w": 0.862,
        "x": 0.069,
        "y": 0.285
      },
      "kind": "table",
      "text": "Comparison table of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fad32d83-92f3-480b-9aee-51c75a22938d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.062,
        "w": 0.145,
        "x": 0.076,
        "y": 0.115
      },
      "kind": "title",
      "text": "NVL-520",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4369097e-ea80-446c-9eff-bf10c74a3cc8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.028,
        "w": 0.455,
        "x": 0.076,
        "y": 0.188
      },
      "kind": "title",
      "text": "Differentiated Product Candidate for ROS1-positive NSCLC Patients",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a4e4045-7367-4117-9144-ab444c2b04fe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "8d89dddf-9b6c-427c-a4c2-b7a70dac4abe",
      "evidence": "table/data: Comparison table of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 metrics.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "693080d1-b9b6-4c04-914f-6f762f54bb76",
      "evidence": "The slide presents a structured grid comparing a lead product candidate against competitors across specific attributes.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 11,
      "beatId": "b013e07a-4c63-44dc-ad23-0b79be40daed",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Competition",
      "beatSlug": "sequoia-pitch-competition",
      "evidence": "The document presents competitive analysis for NVL-520.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fe9c6514-22f1-4979-9b36-391b44fa3c8a",
      "evidence": "The document presents the limitations of current therapies and the potential benefits of Nuvalent's targeted therapies.",
      "position": 0,
      "objective": "The cost of inaction in addressing kinase resistance and selectivity challenges",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}